Ayala Pharmaceuticals Inc (ADXS)

[hovacre]

I think and hope early 2019. I don't feel as though this approval is a slam dunk. Osimertinib first-line was a slam dunk. Durvalumab in stage 3 NSCLC was a slam dunk.

ADXS is relying on the leverage from a major unmet need and the tolerability to allow for an unprecedented surrogate endpoint hit the approval threshold. Do I think it's possible? Yes. Do I think it's certain? No.